V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
MedTech & Diagnostics

Baxter International Executive Compensation (FY25)

BAX · Deerfield, IL · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): May 8, 2026
397 figures on this page: 386 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Andrew Hider
Median of the other named officers
$5,242,744
8 officers, excluding the chief executive
Latest say-on-pay support
=
May 5, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Say-on-pay support: 90.9% → 91.2% (0.3 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Baxter International's chief executive and what were they paid?
Andrew Hider was paid $29,805,182 in total compensation as President and CEO for fiscal 2025.
What was Baxter International's say-on-pay result?
Shareholders supported the say-on-pay proposal with 91.2% of votes cast for or against in favor at the meeting held May 5, 2026 for fiscal 2025.
Which companies are in Baxter International's peer group?
The disclosed peer group includes Abbott Laboratories, Agilent Technologies, Inc., Becton, Dickinson and Company, Boston Scientific Corporation and Danaher Corporation, among others.
What is Baxter International's chief executive pay ratio?
The company reported a chief executive pay ratio of 445:1 for fiscal 2025, against median employee compensation of $72,402.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jos Almeida
Chair, President and Chief Executive Officer
◇—◇◇◇—◇◇
James Saccaro
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Giuseppe Accogli
Executive Vice President and President, Hospital Products
◇—◇◇——◇◇
Cristiano Franzi
Executive Vice President and President, Renal Care and Acute Therapies
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jos Almeida
Former Chair of the Board, President and CEO
◇—◇◇◇—◇◇
Joel Grade
Former Executive Vice President and CFO
◇—◇◇◇—◇◇
Heather Knight
Former Executive Vice President, COO and Interim Group President, Medical Products & Therapies
Served on an interim basis
◇—◇◇◇—◇◇
Alok Sonig
Former Executive Vice President and Group President, Pharmaceuticals
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jos Almeida
Former Chair of the Board, President and CEO
◇—◇—◇—◇◇
Heather Knight
Former Executive Vice President, COO and Interim Group President, Medical Products & Therapies
Served on an interim basis
◇—◇—◇—◇◇
Joel Grade
Former Executive Vice President and CFO
◇◇◇—◇—◇◇
Alok Sonig
Former Executive Vice President and Group President, Pharmaceuticals
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Andrew Hider
President and CEO
◇◇◇◇◇—◇◇
Joel Grade
Former Executive Vice President and CFO
Departed during or after this year
◇—◇◇◇—◇◇
Jos Almeida
Former Chair of the Board, President and CEO
Departed during or after this year
◇—————◇◇
Heather Knight
Former Executive Vice President, COO and Interim Group President, Medical Products & Therapies
Departed during or after this year
Served on an interim basis
◇—◇◇——◇◇
Reazur Rasul
Executive Vice President and Group President, Healthcare Systems & Technologies
◇—◇◇◇—◇◇
Alok Sonig
Former Executive Vice President and Group President, Pharmaceuticals
Departed during or after this year
◇—◇◇——◇◇
Brent Shafer
Non-Executive Chair and Former Executive Chair and Interim CEO
Departed during or after this year
Served on an interim basis
◇◇◇———◇◇
David Rosenbloom
Executive Vice President and General Counsel
◇—◇◇◇—◇◇
Maria Soriano
Group President, Infusion Therapies & Technologies and Pharmaceuticals
◇◇◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Andrew HiderRSU◇——— withheld——◇
Andrew HiderPSU◇◇◇—◇—◇
Andrew HiderPSU◇◇◇—◇—◇
Andrew HiderPSU◇◇◇—◇—◇
Andrew HiderRSU◇——— withheld——◇
Andrew HiderOPTION◇——◇—◇◇
Brent ShaferRSU◇——◇——◇
Heather KnightOPTION◇——◇—◇◇
Heather KnightPSU◇◇◇—◇—◇
Heather KnightRSU◇——◇——◇
Joel GradePSU◇◇◇—◇—◇
Joel GradeOPTION◇——◇—◇◇
Joel GradeRSU◇——◇——◇
Joel GradeRSU◇——— withheld——◇
Reazur RasulOPTION◇——◇—◇◇
Reazur RasulRSU◇——◇——◇
Reazur RasulPSU◇◇◇—◇—◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Maria SorianoOption◇—◇3/6/2035
Option◇—◇3/1/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
David RosenbloomOption◇—◇3/1/2033
Option◇—◇6/1/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/6/2035
Reazur RasulOption◇—◇3/6/2035
Option◇—◇3/2/2032
Option◇—◇3/20/2030
Option◇—◇2/28/2029
Option◇—◇3/1/2028
Option◇—◇3/2/2027
Option◇—◇3/1/2027
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2033
Option◇—◇3/3/2031
Heather KnightOption◇—◇1/27/2026
Option◇—◇1/27/2026
Option◇—◇1/27/2026
Option◇—◇1/27/2026
Option◇—◇1/27/2026
Option◇—◇1/27/2026
Joel GradeOption◇—◇3/6/2035
Option◇—◇12/1/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Jos AlmeidaOption◇—◇10/31/2030
Option◇—◇10/31/2030
Option◇—◇10/31/2030
Option◇—◇3/20/2030
Option◇—◇2/28/2029
Option◇—◇3/1/2028
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/2/2027
Andrew HiderRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇9/2/2035
Alok SonigOption◇—◇3/1/2026
Option◇—◇3/1/2026
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Nancy M. Schlichting
◇◇———◇◇
Stephen N. Oesterle
◇◇———◇◇
David S. Wilkes
◇◇———◇◇
Cathy R. Smith
◇◇————◇
Patricia B. Morrison
◇◇———◇◇
Jeffrey A. Craig
◇◇————◇
Amy A. Wendell
◇◇———◇◇
Stephen H. Rusckowski
◇◇———◇◇
William A. Ampofo II
◇◇———◇◇
Brent Shafer
Board chair
◇—————◇
Michael R. McDonnell served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇
Equity is delivered as Stock.
Stock ownership guideline: 5x annual cash retainer

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Abbott Laboratories ABT
  • Agilent Technologies, Inc. A
  • Becton, Dickinson and Company BDX
  • Boston Scientific Corporation BSX
  • Danaher Corporation DHR
  • DaVita Inc. DVA
  • DENTSPLY Sirona Inc. XRAY
  • Edwards Lifesciences EW
  • GE HealthCare Technologies GEHC
  • Hologic, Inc. HOLX
  • Intuitive Surgical, Inc. ISRG
  • Laboratory Corporation of America Holdings LH
  • Medtronic Public Limited Company MDT
  • Quest Diagnostics Incorporated DGX
  • Stryker Corporation SYK
  • Zimmer Biomet Holdings, Inc. ZBH

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 5, 2026=◇◇◇
2024May 6, 2025=◇◇◇
2023May 7, 2024=◇◇◇
2022May 2, 2023=◇◇◇
2021May 3, 2022=◇◇◇
2020May 4, 2021=◇◇◇
2019May 5, 2020=◇◇◇
2018May 7, 2019=◇◇◇
2017May 8, 2018=◇◇◇
2016May 2, 2017=◇◇◇
2015May 3, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Baxter International files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Baxter International disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Baxter International sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Baxter International's disclosed peer group is defensible, who names Baxter International back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
397 figures on this page: 386 cited to the filing that reported them, 11 calculated from figures it prints.
386 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001193125-26-214680
    Item 5.07 Submission of Matters to a Vote of Security Holders.
  2. 0001628280-26-020330
    CEO Pay Ratio · Director Compensation · Grants of Plan-Based Awards · Outstanding Equity Awards at 202 · and 1 more section
  3. 0001628280-25-023809
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001628280-24-022267
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001628280-23-015793
  6. 0001193125-23-077304
    Summary Compensation Table
  7. 0001193125-22-143745
  8. 0001193125-21-151879
  9. 0001193125-20-137671
  10. 0001193125-19-143553
  11. 0001193125-18-159373
  12. 0001193125-17-158934
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001193125-16-577979
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Baxter International executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/BAX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Baxter International and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers Baxter International discloses

The companies named in BAX's own disclosed peer group.

Abbott LaboratoriesAgilent Technologies, Inc.Becton, Dickinson and CompanyBoston Scientific CorporationDENTSPLY Sirona Inc.Edwards LifesciencesGE HealthCare TechnologiesHologic, Inc.Intuitive Surgical, Inc.Medtronic Public Limited CompanyStryker CorporationZimmer Biomet Holdings, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy